Impaired antigen presentation and potent phagocytic activity identifying tumor-tolerant human monocytes

Biochemical and Biophysical Research Communications

Volumn 423, Issue 2, 2012, Pages 331-337

  Soares Schanoski, Alessandra ^a   Jurado, Teresa ^a   Córdoba, Raúl ^b   Siliceo, María ^a   Fresno, Carlos del ^a   Gómez Piña, Vanesa ^a   Toledano, Victor ^a   Vallejo Cremades, Maria T ^a   Alfonso Iñiguez, Sergio ^a   Carballo Palos, Arkaitz ^a   Fernández Ruiz, Irene ^a   Cubillas Zapata, Carolina ^c   Biswas, Subhra K ^d   Arnalich, Francisco ^a   García Río, Francisco ^a   López Collazo, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

Chronic Lymphocytic Leukemia; TAMs; Tumor tolerant monocytes

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN M2; TRANSACTIVATOR PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; MACROPHAGE; MONOCYTE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL;

ANTIGEN PRESENTATION; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE TOLERANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIPOPOLYSACCHARIDES; MACROPHAGES; MODELS, BIOLOGICAL; MONOCYTES; NEOPLASMS; NUCLEAR PROTEINS; PHAGOCYTOSIS; TRANS-ACTIVATORS;

EID: 84862897715     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.05.124     Document Type: Article

References (39)

1. Porta C., Riboldi E., Totaro M.G., et al. Macrophages in cancer and infectious diseases: the 'good' and the 'bad'. Immunotherapy 2011, 10:1185-1202.
2. del Fresno C., Otero K., Gomez-Garcia L., Gonzalez-Leon M.C., et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J. Immunol. 2005, 174:3032-3040.
3. Saccani A., Schioppa T., Porta C., et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res. 2006, 66:11432-11440.
4. Mantovani G., Maccio A., Pisano M., et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int. J. Cancer 1997, 71:724-731.
5. Sica A., Saccani A., Bottazzi B., et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 2000, 164:762-767.
6. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
7. Brigati C., Noonan D.M., Albini A., Benelli R. Tumors and inflammatory infiltrates: friends or foes?. Clin. Exp. Metastasis 2002, 19:247-258.
8. Mytar B., Woloszyn M., Szatanek R., et al. Tumor cell-induced deactivation of human monocytes. J. Leukoc. Biol. 2003, 74:1094-1101.
9. Turnis M.E., Song X.T., Bear A., et al. IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J. Immunol. 2010, 185:4223-4232.
10. Biswas S.K., Lopez-Collazo E. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 2009, 30:475-487.
11. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
12. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
13. Mantovani A., Sozzani S., Locati M., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
14. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
15. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
16. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11 889-896.
17. Mantovani A., Sica A., Sozzani S., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
18. Sica A., Larghi P., Mancino A., et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
19. Deepak P., Kumar S., Acharya A. Interleukin-13-induced type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-kappaB and preservation of IkappaBalpha in a T cell lymphoma. Clin. Exp. Immunol. 2007, 149:378-386.
20. S.H. Swerdlow, E. Campo, N.L. Harris, et al. (Eds.), World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, fourth ed., IARC Press, Lyon, 2008.
21. del Fresno C., Soler-Rangel L., Soares-Schanoski A., et al. Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J. Endotoxin Res. 2007, 13:39-52.
22. del Fresno C., Gomez-Pina V., Lores V., et al. Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS ONE 2008, 3:e2667.
23. Escoll P., del Fresno C., Garcia L., et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem. Biophys. Res. Commun. 2003, 311:465-472.
24. Gomez-Pina V., Soares-Schanoski A., Rodriguez-Rojas A., et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J. Immunol. 2007, 179:4065-4073.
25. de las Heras B., Hortelano S., Giron N., et al. Kaurane diterpenes protect against apoptosis and inhibition of phagocytosis in activated macrophages. Br. J. Pharmacol. 2007, 152:249-255.
26. Pinheiro da Silva F., Aloulou M., Skurnik D., et al. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat. Med. 2007, 13:1368-1374.
27. Hernandez-Fuentes M.P., Warrens A.N., Lechler R.I. Immunologic monitoring. Immunol. Rev. 2003, 196:247-264.
28. Adams A.B., Williams M.A., Jones T.R., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 2003, 111:1887-1895.
29. Lopez-Collazo E., Fuentes-Prior P., Arnalich F., del Fresno C. Pathophysiology of interleukin-1 receptor-associated kinase-M: implications in refractory state. Curr. Opin. Infect. Dis. 2006, 19:237-244.
30. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42:717-727.
31. del Fresno C., Garcia-Rio F., Gomez-Pina V., et al. Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J. Immunol. 2009, 182:6494-6507.
32. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110:191-202.
33. Xie Q., Gan L., Wang J., Wilson I., Li L. Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol. Immunol. 2007, 44:3453-3461.
34. LeibundGut-Landmann S., Waldburger J.M., Krawczyk M., et al. Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur. J. Immunol. 2004, 34:1513-1525.
35. Guo R., Zou P., Fan H.H., et al. Inhibition effect of CIITA anti-sense cDNA on the expression of MHCII molecules of Hela cells 2003, 24:636-639.
36. Jabrane-Ferrat N., Nekrep N., Tosi G., et al. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?. Int. Immunol. 2003, 15:467-475.
37. A Mantovani, A Sica Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 2010, 22:231-237.
38. Davies B., Edwards S.W. Interactions between human monocytes and tumour cells. Monocytes can either enhance or inhibit the growth and survival of K562 cells. Br. J. Cancer 1992, 66:463-469.
39. Mytar B., Siedlar M., Woloszyn M., et al. Induction of reactive oxygen intermediates in human monocytes by tumour cells and their role in spontaneous monocyte cytotoxicity. Br. J. Cancer 1999, 79:737-743.